200 related articles for article (PubMed ID: 29362485)
1. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.
Smirnova J; Kabin E; Järving I; Bragina O; Tõugu V; Plitz T; Palumaa P
Sci Rep; 2018 Jan; 8(1):1463. PubMed ID: 29362485
[TBL] [Abstract][Full Text] [Related]
2. Design of intrahepatocyte copper(I) chelators as drug candidates for Wilson's disease.
Gateau C; Delangle P
Ann N Y Acad Sci; 2014 May; 1315():30-6. PubMed ID: 24611802
[TBL] [Abstract][Full Text] [Related]
3. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.
Delangle P; Mintz E
Dalton Trans; 2012 Jun; 41(21):6359-70. PubMed ID: 22327203
[TBL] [Abstract][Full Text] [Related]
4. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
6. Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease.
Plitz T; Boyling L
Xenobiotica; 2019 Mar; 49(3):332-338. PubMed ID: 29460662
[TBL] [Abstract][Full Text] [Related]
7. Wilson disease: genetic basis of copper toxicity and natural history.
Schilsky ML
Semin Liver Dis; 1996 Feb; 16(1):83-95. PubMed ID: 8723326
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy.
McQuaid A; Mason J
J Inorg Biochem; 1991 Feb; 41(2):87-92. PubMed ID: 2033396
[TBL] [Abstract][Full Text] [Related]
9. Dissolution of copper-rich granules in hepatic lysosomes by D-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats.
Klein D; Lichtmannegger J; Heinzmann U; Summer KH
J Hepatol; 2000 Feb; 32(2):193-201. PubMed ID: 10707858
[TBL] [Abstract][Full Text] [Related]
10. Extending the mode of action of triethylenetetramine (trientine): Autophagy besides copper chelation.
Pietrocola F; Castoldi F; Zischka H; Kroemer G
J Hepatol; 2020 Oct; 73(4):970-972. PubMed ID: 32684364
[No Abstract] [Full Text] [Related]
11. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Larsen A; Schilsky ML; Ott P; Sandahl TD
J Hepatol; 2024 Apr; 80(4):586-595. PubMed ID: 38081365
[TBL] [Abstract][Full Text] [Related]
12. Wilson disease - currently used anticopper therapy.
Członkowska A; Litwin T
Handb Clin Neurol; 2017; 142():181-191. PubMed ID: 28433101
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of Wilson disease].
Smolarek C; Stremmel W
Z Gastroenterol; 1999 Apr; 37(4):293-300. PubMed ID: 10378366
[TBL] [Abstract][Full Text] [Related]
14. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease.
Kazemi K; Geramizadeh B; Nikeghbalian S; Salahi H; Bahador A; Reza Nejatollahi SM; Dehghani SM; Dehghani M; Kakaei F; Malek-Hosseini SA
Exp Clin Transplant; 2008 Dec; 6(4):261-3. PubMed ID: 19338486
[TBL] [Abstract][Full Text] [Related]
15. Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Schilsky ML; Ott P; Sandahl TD
Hepatology; 2024 May; 79(5):1065-1074. PubMed ID: 38088886
[TBL] [Abstract][Full Text] [Related]
16. Effects of tetrathiomolybdate and penicillamine on brain hydroxyl radical and free copper levels: a microdialysis study in vivo.
Zhang JW; Liu JX; Hou HM; Chen DB; Feng L; Wu C; Wei LT; Li XH
Biochem Biophys Res Commun; 2015 Feb; 458(1):82-5. PubMed ID: 25634697
[TBL] [Abstract][Full Text] [Related]
17. Excess copper chelating therapy for Wilson disease induces anemia and liver dysfunction.
Harada M; Miyagawa K; Honma Y; Hiura M; Shibata M; Matsuhashi T; Abe S; Harada R; Tabaru A
Intern Med; 2011; 50(14):1461-4. PubMed ID: 21757830
[TBL] [Abstract][Full Text] [Related]
18. Effect of glutathione depletion on removal of copper from LEC rat livers by tetrathiomolybdate.
Ogra Y; Miyayama T; Anan Y
J Inorg Biochem; 2010 Aug; 104(8):858-62. PubMed ID: 20427090
[TBL] [Abstract][Full Text] [Related]
19. Chelating principles in Menkes and Wilson diseases: Choosing the right compounds in the right combinations at the right time.
Horn N; Møller LB; Nurchi VM; Aaseth J
J Inorg Biochem; 2019 Jan; 190():98-112. PubMed ID: 30384011
[TBL] [Abstract][Full Text] [Related]
20. Wilson disease--a practical approach to diagnosis, treatment and follow-up.
Medici V; Rossaro L; Sturniolo GC
Dig Liver Dis; 2007 Jul; 39(7):601-9. PubMed ID: 17382611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
